Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTV3XPL)

• DTT Name: T-cell surface glycoprotein CD3 gamma (CD3G) DTT Info
• Gene Name: CD3G

Molecule-Related Drug & Molecule List

2 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tebentafusp	DMUJ1WV	Gastric cancer	2B72	Approved	[1]
Teplizumab	DMZ3P6C	Type-1 diabetes	5A10	Approved	[2]

5 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ertumaxomab	DM5Z3VP	Breast cancer	2C60-2C65	Phase 2	[3]
MGD007	DMAHWLR	Colorectal cancer	2B91.Z	Phase 1/2	[4]
Autologous T-cell therapy	DMOAET3	Prostate cancer	2C82.0	Phase 1	[5]
MEDI-565	DMFWPLQ	Gastrointestinal cancer	2C11	Phase 1	[4]
MT-110	DMPCUN5	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
• [4] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [5] Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38.
• [6] EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74.